From GlobeNewswire.: 2024-05-24 08:00:00

Genelux Corporation announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants at a combined offering price of $4.00 per share. This is expected to result in gross proceeds of approximately $27.5 million, with net proceeds providing working capital until the first quarter of 2026. The offering is expected to close on or about May 29, 2024. Genelux’s most advanced product candidate, Olvi-Vec, is being evaluated in a Phase 3 registrational trial for patients with platinum-resistant/refractory ovarian cancer. Guggenheim Securities is acting as the sole book-running manager for the offering.



Read more at GlobeNewswire.: Genelux Corporation Announces Pricing of Approximately